Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Altus off after Genentech returns ALTU-238 rights

ALTU fell $4.38 (44%)

Read the full 48 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE